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ABSTRACT: A fundamental question is how to detect likely successful anticancer treatments based on 
nanotechnology. We confront this question here by analyzing the trajectories of nanotechnologies applied 
to path-breaking cancer treatments, which endeavour to pinpoint ground-breaking and fruitful directions in 
nanomedicine. Results tend to show two main technological waves of cancer treatments by 
nanotechnology applications. The early technological wave in the early 2000s was embodied in some 
types of chemotherapy agents with a broad spectrum, while after 2006, the second technological wave 
appeared with new nano-technological applications in both chemotherapy agents and molecular target 
therapy. The present study shows new directions of nanotechnology-based chemotherapy and -molecular 
cancer therapy in new treatments for breast, lung, brain and colon cancers. A main finding of this study is 
the recognition that, since the late 2000s, the sharp increase of several technological trajectories of 
nanotechnologies and anticancer drugs seems to be driven by high rates of mortality of some types of 
cancers (e.g. pancreatic and brain ones) in order to find more effectiveness anticancer therapies that 
increase the survival of patients. The study here also shows that worldwide leader countries in these vital 
research fields and in particular the specialization of some countries in applications of nanotechnology to 
treat specific cancer (e.g. Switzerland in prostate cancer, Japan in colon, China in ovarian and Greece in 
pancreatic cancer). These ground-breaking technological trajectories are paving new directions in 
biomedicine and generating a revolution in clinical practice that may lead to more effective anticancer 
treatments in a not-too-distant future. 
Keywords: Nanotechnology, Nanoscience, Biomedicine, Nanomedicine, Target Therapy, 
Chemotherapy, Cancer, Bibliometrics, Publications, Technological Trajectories. 
JEL Codes: C89; O30, C53, I10 
Acknowledgments: This research started by the authors in 2012 and it has been developed in 2013 while Mario Coccia was 
visiting scholar at the UNU-MERIT in Maastricht. We thank Prof. Bart Verspagen for fruitful suggestions to this paper. 
Mario Coccia gratefully acknowledges the CNR - National Research Council of Italy for financial support to this research 
project by the short mobility program at UNU-MERIT. Preliminary results have been presented at S.NET 4th Annual 
Meeting -Fourth annual conference of the society for the study of nano science and emerging technologies (October 22-25, 
2012), University of Twente (The Netherlands). The usual disclaimer applies.  
Mario Coccia* 
National Research Council of Italy  
Institute for Economic Research on Firm and Growth 
 
CNR-CERIS Collegio Carlo Alberto - via Real Collegio, n. 30  
10024 Moncalieri (Torino) – ITALY 
Tel.: +39 011 68 24 925;  
fax : +39 011 68 24 966;  
email: m.coccia@ceris.cnr.it 
Lili Wang 
United Nations University 
The Maastricht Economic and Social Research Institute 
on Innovation and Technology 
UNU-MERIT- Keizer Karelplein, n. 19  
6211 TC Maastricht – The Netherlands 
Tel.:+ 31 (0) 43-3884456 
email: wang@merit.unu.edu 
 
      Coccia M., Wang L., Working Paper Cnr-Ceris, N° 01/2014 
CONTENTS 
1. Introduction and the problem ................................................................................................... 5
2. Theoretical background and related works .............................................................................. 6
3. Method of research ................................................................................................................... 8
4. Experimental results and discussions ..................................................................................... 11
5. Lessons learned and concluding observations ....................................................................... 19
Appendix ..................................................................................................................................... 21 
References ................................................................................................................................... 23 
4 
Coccia M., Wang L., Working Paper Cnr-Ceris, N° 01/2014 
1. INTRODUCTION AND THE
PROBLEM
nterdisciplinary theoretical and 
experimental results related to 
nanoscience and nanotechnology in the 
life sciences are supporting the diagnosis, 
monitoring, prevention and treatment of 
diseases. Nanotechnology in medicine has 
generated a vital technological change and as 
a consequence a revolution in clinical practice 
(Islam and Miyazaki, 2010; Rafols and 
Meyer, 2010; Coccia, 2012a; Wolinsky et al., 
2012; Madeira et al., 2013)1. No and Park 
(2010), using patent citations, argue that the 
interaction of biotechnology and 
nanotechnology may provide important 
signals for future patterns in nano-
biomedicine (cf. Sylvester and Bowman, 
2010; Coccia, 2012). In fact, nanotechnology 
has a high potential of development for 
biomedical purposes such as the ground-
breaking applications in new therapies for 
oncology (cf. Lim et al., 2010; Coccia, 2012a; 
2012b).  
Bibliometrics is an important approach for 
investigating emerging fields of 
nanotechnology (Arora et al., 2013).  
In fact, some studies, based on publications, 
show that the patterns of nanotechnology 
research are spreading among different 
scientific domains and pathways, generating 
new technological paradigms mainly in 
chemistry, medicine and engineering research 
fields (cf. Coccia, 2012a; Robinson et al., 
2013). 
As far as the performance in 
nanotechnology research is concerned, 
Shapira and Wang (2010) show the leadership 
1 cf. also Genet et al., 2012; Chen et al., 2013; 
Tierney et al., 2013, von Raesfeld et al., 2012. 
of some countries, such as the US and China, 
which are considered among the top 
nanotechnology research publishing countries. 
This result can be due to high R&D 
investments in this vital research field and 
incentives given to researchers to publish in 
Web of Science indexed journals (Lin and 
Zhang, 2007; Shapira and Wang, 2009). 
However, Youtie et al. (2008) claim that 
publication counts do not necessarily equate 
to publication influence. 
An interesting problem that deserves to be 
analyzed is how to detect the path-breaking 
directions of nanotechnology trajectories 
applied for vital anti-cancer treatments. In 
particular, we confront this main issue by 
analyzing:  
• the directions of technological trajectories
of the most common anticancer drugs
(chemotherapy agents, substances, or
target therapies) inserted in nanoparticle to
treat cancers with more effectiveness;
• the evolutionary pathways of types of
cancer where there is a high intensive
research activity of treatments that use
nanotechnology;
• the countries that are best performers in
applications of nanotechnologies to treat
cancer and the specialization of
countries to treat specific  cancer  by
nanotechnology.
This study can provide important 
information concerning emerging and fruitful 
directions of nanotechnology applied in 
ground-breaking anti-cancer treatments that 
may generate a revolution in clinical practice 
to improve human health and quality of life in 
a not-too-distant future. 
I 
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2. THEORETICAL BACKGROUND 
AND RELATED WORKS 
Breakthroughs in nanotechnology are 
providing “a new dimension” to medicine (da 
Rocha et al., 2014). Therapies integrated in 
nanoparticles or cooperative nanosystems are 
spurring new insights to groundbreaking 
cancer treatments. The strategy of the 
National Cancer Institute with 
nanotechnology started in 2004 to support 
multidisciplinary researchers in the 
applications of nanotechnology to new anti-
cancer treatments (Hull et al., 2013). In fact, 
R&D in this field has experienced an 
exponential growth since the early 2000’s, 
such that “cancer nanotherapeutics are 
progressing at a steady rate” (Bertrand et al., 
2013). For this reason, pharmaceutical 
companies have formed strategic alliances and 
partnerships with biotechnology firms to 
improve and accelerate the drug discovery 
process (Coccia, 2014a).  
A fundamental question in the field of the 
economics of innovation is how trajectories of 
scientific fields evolve, expand, converge (or 
diverge) and break out. Bibliometrics plays a 
main role to detect and map this continuous 
evolution (Huang et al., 2014), being 
associated with powerful software to analyze 
diverse and large volume of data. Motoyama 
and Eisler (2011, p. 1174) consider 
bibliometrics the “primary method of gaging 
progress in nanotechnology”. As a matter of 
fact, social scientists, more and more, use 
bibliometric and scientometric approaches to 
detect and analyse trajectories in the wide 
domain of cancer nanotechnology research 
(Wang et al., 2013).  
These approaches play an important role to 
explore the current evolutionary knowledge 
growth of trajectories of nanotechnology that 
may support future patterns of technological 
innovation in emerging and cutting-edge areas 
of biomedical sciences. De Bellis (2009) 
observes that citation analysis, a bibliometric 
technique, is a prominent feature in the study 
of new scientific knowledge.  
Thomas et al. (2011) discuss a nanoparticle 
ontology for cancer nanotechnology research 
to represent knowledge underlying 
nanomaterials involved in cancer research. 
Huang et al. (2010) show that there are 
different search strategies for nanotechnology 
research such as citation analyses, core 
journal strategies (core is when the journal has 
nano in its title), lexical queries, etc. (cf. 
Mogoutov and Kahane, 2007). Zitt et al. 
(2011) argue that keywords act as main 
signals of scientific inquiry, while citations 
are more effective in identifying research 
streams. Using a keyword mining approach, 
Wang et al. (2013) find that the general trend 
of integration in the application of 
nanotechnology fields is converging.  
Arora et al. (2013) employ structured text-
mining software to profile keyword terms and 
identify new nanotechnology-related 
keywords. This strategy shows the main role 
of several emerging cited-subject categories 
of nanotechnology, particularly in the 
biomedical sciences. Instead, Zitt and 
Bassecoulard (2006) employ citation networks 
to expand their corpus of nanotechnology 
publications. Leydesdorff and Zhou (2007) 
present an approach based on a core set of six 
nanotechnology journals and citation and 
network analysis to provide fruitful results in 
understanding this research field.  
Among all the research areas, biomedicine 
is one of the key scientific fields where 
nanotechnologies are providing vital 
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innovative applications in diagnostics and in 
therapeutics (cf. Hu et al., 2011; da Rocha et 
al., 2014; Gao et al., 2013). Coccia (2012a) 
displays that the current convergence of 
genetics, genomics and nanotechnology is the 
scientific backbones of new technological 
paradigms and trajectories in biomedical 
sciences. This convergence of vital scientific 
fields is supporting innovative anticancer 
treatments and a revolution in clinical 
practice.  
There are several nanotechnologies applied 
in biomedicine for supporting anti-cancer 
treatments (Chen et al., 2011; He et al. 2010; 
Luo et al., 2011). For instance, Nanoparticles 
(NPs) can be designed to selectively target the 
specific tissue/organ in which there is the 
cancer (Coccia, 2012b).  
In addition, functionalizing the surface of 
NPs with specific and appropriate ligands can 
allow their use as drug carriers to target them 
selectively to the tissue/organ affected by 
cancer (see Pöselt et al., 2012; Shukoor et al., 
2012; Shukoor et al., 2011). Nanoparticles 
can also act as carriers for drugs, which can be 
contained into organic nanomicelles or porous 
inorganic nanoparticles that, by apt bioactive 
systems, can target tumoral cells of the body 
(see Yao et al., 2011; Goel et al., 2010).  
Quantum Dots (QDs), instead, are a specific 
subset of NPs (Obonyo et al., 2010; Byers and 
Hitchman, 2011; Rosenthal et al., 2011). The 
QDs in medicine are mainly applied as 
targeted drug delivery (Jain, 2012).  
Carbon nanotubes are an allotropic form of 
carbon, having cylindrical structure and can 
be used to deliver drugs against cancer cells, 
protecting them towards external agents 
(Ezzati Nazhad Dolatabadi et al., 2011; 
Bareket et al., 2010). In fact, carbon 
 
nanotubes combined with cytotoxic 
(antineoplastic or chemotherapy) agents are a 
key area of development for biomedical 
sciences (Shapira et al., 2011).  
Some edge areas of bio-nano-medical 
applications (closer to molecular biology) are 
still at the stage of first experimental trials, 
such as the combination between nanoparticle 
and siRNA2. 
Gao et al. (2013) show that nanomedicine, 
based on a targeted drug delivery system, 
significantly improve cancer metastasis 
treatments.  
Hence, nanotechnology-based approaches 
are a promising research field for early-stage 
diagnosis and for advanced treatments of 
cancers that have high rate of mortality (Patra 
and Truner, 2014; Coccia 2014; Coccia, 2013; 
2012c).  
GLOBOCAN (2008) shows high mortality 
(in terms of Age-standardized rate3), in 
comparison to incidence, by cancer of the 
lung and bronchus (19.3), breast (12.4), 
colorectum (8.2), cervix uteri (7.8), prostate 
(7.4), ovary (3.8), pancreas (3.7) and brain 
(2.5).  
 
2 Small interfering RNA (siRNA), sometimes known 
as short interfering RNA or silencing RNA, is a class 
of double-stranded RNA molecules that play a 
variety of roles in biology.  
3 Mortality: Population weighted average of the area-
specific country rates applied to the 2008 area 
population.  
Age-standardised rate (W): A rate is the number of 
new cases or deaths per 100 000 persons per year. An 
age-standardised rate is the rate that a population 
would have if it had a standard age structure. 
Standardization is necessary when comparing several 
populations that differ with respect to age because 
age has a powerful influence on the risk of cancer.  
 7 
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In general, these serious diseases can be 
treated with:  
a) Chemotherapy agents that are cytotoxic 
anti-neoplastic drugs to destroy cancer 
cells; 
b) Targeted cancer therapies that are: “drugs 
or other substances that block the growth 
and spread of cancer by interfering with 
specific molecules involved in tumor 
growth and progression” (National cancer 
institute as quoted by Coccia, 2012b, p. 
276);  
c) Antiestrogen therapy, such as tamoxifen, 
that blocks the effects of the hormone 
estrogen in the breast;  
d) Cancer siRNA therapy (SiRNA seem to 
substantially better than antibodies, 
because they might easily applicable to any 
therapeutic target including intracellular 
factors and even transcription factors. The 
selectivity of siRNA inhibitors of gene 
expression might improve targeted cancer 
therapeutics, but the means for systemic 
administration and targeted distribution to 
disseminated metastatic lesions are needed; 
see Schiffelers et al., 2004);  
e) Chemopreventive substances, such as 
curcumin.  
We confront the initial problems of the 
paper by analyzing the evolution and fruitful 
directions of trajectories of the 
nanotechnology applied to improve these 
different types of treatments for above-
mentioned cancers with higher rate of 
mortality.  
3. METHOD OF RESEARCH 
We analyse evolution and direction of the 
most important and ground-breaking 
anticancer treatments based on: 
• Nanotechnology with chemotherapy agents 
(cytotoxic anti-neoplastic drugs) such as 
Paclitaxel, Cisplatin, Gemcitabine, 
Carboplatin, Docetaxel, Doxorubicin, etc.; 
• Nanotechnology with molecular cancer 
therapies such as herceptin, cetuximab, 
lapatinib, tamoxifen (antiestrogen), and 
cancer si-RNA therapy;  
• Nanotechnology with chemoprevention 
substances such as curcumin.  
Considering the high mortality of some 
types of cancer discussed in the previous 
section, seven cancer fields - brain cancer, 
breast cancer, colon cancer, lung cancer, 
ovarian cancer, pancreatic cancer and prostate 
cancer – are covered in our analysis.   
The performance of this paper is based on a 
set of publication and citation data collected 
from Scopus in the 2013. The search query 
was developed by the combination of nano 
and each cancer field, searched from abstracts, 
keywords and titles. The time span covers 13 
years (2000-2012). Research records prior to 
2000 were not included because of 
insignificant publication numbers. To refine 
the data quality, we excluded publications that 
appeared in less relevant sources, e.g. journals 
in social science, etc., but we focus on 12 
important journal categories4. In total, this 
4 These 12 journal categories are: 1) Medicine, 2) 
Biochemistry, Genetics and Molecular Biology, 3) 
Pharmacology, Toxicology and Pharmaceutics, 4) 
Health Professions, 5) Nursing, 6) Engineering, 7) 
Chemistry, 8) Agricultural and Biological Sciences, 
9) Immunology and Microbiology, 10) Neuroscience, 
11) Chemical Engineering, 12) Materials Science.  
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study covers 5,080 (nano & cancer treatment) 
publications, including 1,440 cited references 
from nanotechnology. VantagePoint and 
Ucinet software are used for accurate and 
deeper analysis as well as for visualizing 
technological networks.  
After gathering all the publication records, 
we classify the applications of 
nanotechnology into different groups by 
keywords. We focus on vital types of 
anticancer drugs/therapies applied by means 
of nanotechnology.  
The nanotechnology and anticancer drug 
groups are: 01) nano & paclitaxel, 02) nano & 
cisplatin, 03) nano & gemcitabine, 04) nano & 
carboplatin, 05) nano & docetaxel; 06) nano 
& doxorubicin, 07) nano & herceptin (or 
trastuzumab), 08) nano & lapatinib, 09) nano 
& Cetuximab, 10) nano & tamoxifen, 11) 
nano & siRNA and 12) nano & curcumin5. In 
particular, No. 01-No. 06 are new anti-cancer 
treatments based on chemotherapy agents 
applied by nanotechnology, while target 
therapies applied with nanotechnology are 
No.07, 08, 09; antiestrogen therapy 
(Tamoxifen) applied by nanotechnology is 
No. 10; cancer siRNA therapy is No. 11 and 
chemoprevention substance is No. 12. 
Some technological fields, such as: 13) nano 
& EGFR (or epidermal)6, 14) nano & HER2 
(or HER-2), 15) nano & RNA, 16) nano & 
 
5 Number 13, 14, 15 and 16 are not included in the 
figures in next section, because these keywords do 
not concern anticancer drugs but EGFR (epidermal 
growth factor receptor: the protein found on the 
surface of some cells and to which epidermal growth 
factor binds, causing the cells to divide.), HER2 (a 
protein involved in normal cell growth), etc. 
6  For EGFR and HER2, see previous footnote.  
PLGA (poly lactic glycolic acid)7, which also 
provide substantial information about ground-
breaking applications of cancer treatments via 
nanotechnology, are included while gathering 
our publication database. However, due to the 
fact that they do not represent anticancer 
drugs, they are not illustrated in the 
technology-specific analysis.  
The study is conducted by the following 
steps: 
• Step 1: To examine the evolutionary 
growth of nanotechnology applied in 
cancer research.  From the perspective of 
target fields, the evolutionary development 
of nanotechnology applied in cancer 
treatment field are mapped.  
• Step 2: From the perspective of applied 
nanotechnology, the vital role of 
nanotechnology applied with some 
anticancer treatments is explored by 
citation analysis.  
• Step 3: To link (within a network) specific 
nanotechnology and anticancer drugs with 
a specific cancer field.  
Remark: Some evolutionary trends are 
plotted by a Log-Linear Regression model8, 
estimated by Ordinary Least Squares Method 
in order to approximately measure and assess, 
by the coefficient of regression, the 
acceleration of some technological 
trajectories.  
7 Poly(lactic-co-glycolic acid) (PLGA) is one of the 
most successfully developed biodegradable polymers. 
Among the different polymers developed to 
formulate polymeric nanoparticles, PLGA has 
attracted considerable attention due to its attractive 
properties (Danhier F. et al., 2012). 
8 The estimation of a linear relationship is based on 
the following model: LogYi=α+βTi+ɛi; i=1, …, n 
(Ti=Time; ɛi=Errors).  
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Given that not all the nanotechnologies are 
equally applied in all cancer treatments, we 
adopt network analysis to link and detect the 
specific nanotechnology and anticancer 
drugs/therapies to cancer field.  
• Step 4: To spot the top profile countries 
which are in the leading position in 
applying new cancer treatments by 
nanotechnology.  
Moreover if we suppose i is a certain 
country and j is the cancer field, the research 
weight of country i in field j can be calculated 
by i-country’s publications in j-field divided 
by all global publications in j-field. Hence, the 
general research weight index (𝜃𝑖) of i-
country is the sum of i-country’s research 
weight in all cancer fields. This is given by:  
  𝜃𝑖 = � 𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠𝑖𝑗𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑤𝑜𝑟𝑙𝑑𝑤𝑖𝑑𝑒𝑗𝑛
𝑗=1
 
(1) 
 
• Step 5: To examine the internal 
specification of each top country.  
Each country may have their own 
concentration of research in nanotechnology 
applied to treat specific types of cancer. 
Therefore, we use the following index to 
examine country’s specialization in the seven 
cancer treatment areas. Specialization ratio of 
country i in field j, defined as 𝐶𝑖𝑗, is the ratio 
of its publications in j field divided by its total 
publications in all cancer fields.  
Specialization ratio of worldwide in j field, 
written as 𝑊𝑖𝑗, is the ratio of worldwide 
publications in j field divided by total 
publication in all cancer fields worldwide. 
The disparity between 𝐶𝑖𝑗 and 𝑊𝑖𝑗 is the 
specialization index of country i in field j, 
which is taken as γij . 
 
𝐶𝑖𝑗 = 𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑗𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑖 ;    𝑗 = 1, … ,𝑛.     
(2) 
 
𝑊𝑗 = 𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑗𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑊𝑜𝑟𝑙𝑑𝑤𝑖𝑑𝑒 ;  j=1,…,n 
(3) 
 
𝛾𝑖𝑗 = 𝐶𝑖𝑗 − 𝑊𝑗;    𝑗 = 1, … ,𝑛.   
(4) 
 
A high level of index γij indicates that the 
high specialization of the country i in the 
specific research field j. In particular, γ>0 
means high specialization in the scientific 
research in this type of cancer, whereas if γ < 
0 means that there is lower specialization. 
High values γ means a higher intensive 
research activity in the specific cancer area by 
application of nanotechnology to cancer 
treatments. In addition, this study intends to 
test the following hypothesis (HP) by a 
hypothetical-deductive approach à la Carl 
Hempel:  
 
HP: High growth of trajectories of 
nanotechnology applied to new 
anticancer treatments is due to 
higher rate of mortality of some 
types of cancer.  
 
In order to validate this HP, a main 
statistical technique applied is the 
nonparametric measure of association by the 
coefficients of correlation Tau-b of Kendall 
and of Spearman between average nano-
citations and ratio mortality/incidence. This 
research departs from the position that there 
can be no adequate knowledge where causes 
are unknown and analyses the phenomena to 
be explained by a scientific realism. 
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4. EXPERIMENTAL RESULTS AND 
DISCUSSIONS 
Figure 1 shows that the number of scientific 
publications concerning cancer treatments 
associated to nanotechnology is growing over 
years. The highest magnitude of scientific 
output in these research fields is driven by 
cancers that have a high incidence rate, such 
as breast, lung and colon cancer. In addition, 
it is interesting to note that growth rate of 
scientific research by brain and pancreatic 
cancer is increased sharply in later years, 
although they had a low activity of scientific 
production in early 2000. In fact, coefficient 
of regression (a proxy of increase over time) 
by brain and pancreatic cancer trends is higher 
than Breast cancer. In the long run, there 
shows a convergence of these trajectories over 
time. This general trend can be further 
approved by the citation of nanotechnology in 
these fields (see Figure 1A in Appendix).  
To take the size of different research fields 
into account, we calculate the average of nano 
citation intensity concerning nano applications 
in the studied seven cancer fields. In 
particular, Table 1 shows that nanotechnology 
applications have the highest citation intensity 
in brain cancer. Following brain cancer, 
pancreatic cancer is the second field where 
nanotechnology has been intensively applied 
to new anticancer treatments, with average 
nano-citation intensity at 11.9%.  
Albeit the total research output of 
nanotechnology in breast cancer, colon cancer 
and prostate cancer, as showed in Figure 1, is 
rather high, the citation intensity of 
nanotechnology in these three cancer fields is 
relatively low (see the last three rows of the 
first column in Table 1).  
 
 
Note: The logarithm of publications is taken to better present the values. This figure also shows the estimate 
relationships by ordinary least square (and R square) to indicate approximate rate of growth of some trends.  
Source: Authors’ own calculation.  
Figure 1: Publications of cancer treatments by nanotechnology in different typology 
of cancer (2000-2012)  
y = 0.2023t + 3.8017 
R² = 0.966(Breast) 
y = 0.2758t + 1.4181 
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Table 1: Intensity of nano citation (standardized) and mortality ratio in cancer field  
Field 
Average of nano citation 
intensity in cancer field 
(average of 2009-2012) 
RaMI=Ratio of 
Mortality/incidence 
Brain-cancer 19.3% 0.714 
Pancreatic-cancer 11.9% 0.949 
Ovarian-cancer 8.7% 0.603 
Lung-cancer 8.3% 0.843 
Breast-cancer 8.1% 0.319 
Colon-cancer 6.8% 0.477 
Prostate-cancer 6.8% 0.265 
Coefficients of Correlation between average nano-citations and 
ratio τ are: Tau-b of Kendall= +0.59; Spearman =+0.76 (sig. 0.05) 
Note: 1) The percentage of nano citation is standardized. Namely, the citation intensity is calculated by the citation of 
nano in that year divided by the total publications of that cancer field in all previous years. 
2) Due to the lack of citation data for some small research fields in early years, the average is taken  
between 2009 and 2012.  
Source: Authors’ own calculation. 
 
 
In order to test the HP, Table 1 shows the 
combination of factors of the mortality and 
incidence rate of different cancer fields.  
It is interesting to observe that cancer fields 
in which the Ratio of Mortality to Incidence 
(Called RaMI) is high, all have high nano 
citation density, and vice versa.  
In fact, coefficients of correlation between 
average nano-citations and ratio RaMI are: 
Tau-b of Kendall= +0.59; Spearman =+0.76 
(sig. 0.05). This result suggests that cancer 
fields, where incidence is low while mortality 
is high, although the total joint research output 
with nanotechnology is relatively low, the 
intensity of nanotechnology applications to 
ground-breaking anticancer treatments is very 
high.  
This reveals that nanotechnology plays a 
crucial role in these specific cancers (with 
high mortality rate) because it might support 
new technological avenues to find effective 
therapies in order to increase the survival of 
patients.  
This result validates the HP and is 
confirmed by Figure 2, where the high 
intensive citations of nanotechnology research 
are exactly in brain and pancreatic cancer (cf. 
also the Figure 1A).  
 
 
 
 
 12 
 
Coccia M., Wang L., Working Paper Cnr-Ceris, N° 01/2014                                              
 
 
Note: The logarithm of publications is taken to better present the values.  
Source: Authors’ own calculation. 
Figure 2: Citation intensity of nanotechnology in cancer fields per different typology 
of cancer (2009-2012) 
 
Figure 3 shows the trajectories of main 
anticancer drugs applied by nanotechnology. 
This figure displays interesting findings. First 
of all, the scientific research of chemotherapy 
agents applied through nanotechnologies is 
started in 2002-2003 (i.e. No.01 - No.06), 
whereas the new molecular target therapies 
leveraged with nanotechnologies are started 
later, 2007 or thereabouts (No. 07, 08, 09, 10, 
11, 12). As a matter of fact, since 2002 the 
highest intensity of scientific research in new 
anticancer treatments is based on well-know 
chemotherapy agent paclitaxel (discovered in 
US during 1960s) and doxorubicin 
(discovered in Italy over 1950s) with 
nanotechnology. The high growth of these 
anticancer drugs can be due to broad spectrum 
of applications to treat different cancer: 
Doxorubicin is commonly used to treat some 
leukemias and Hodgkin's lymphoma, as well 
as cancers of the bladder, breast, stomach, 
lung, ovaries, thyroid, soft tissue sarcoma, 
multiple myeloma, and others. Instead, 
paclitaxel albumin-stabilized nanoparticle 
formulation is a form of paclitaxel contained 
in nanoparticles (very tiny particles of 
protein). This form seems to work better than 
other forms of paclitaxel and has fewer side 
effects. National Cancer Institute (2013) states 
that paclitaxel albumin-stabilized nanoparticle 
formulation is approved to be used alone or 
with other drugs to treat: 
• Breast cancer that has recurred (come 
back) or metastasized (spread to other parts 
of the body). 
• Non-small cell lung cancer that is locally 
advanced or has metastasized and cannot 
be treated with surgery or radiation 
therapy. It is used with carboplatin. 
• Pancreatic cancer that has metastasized. It 
is used with gemcitabine hydrochloride. 
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Note:1) Chemotherapy agents applied with nanotechnologies are No. 01-No.06, while molecular target therapies and 
other anticancer treatments are No.07-No.12. 
2) No.13-No.16 are not included in this figure because they do not concern anticancer drugs but EGFR, HER2, 
etc.   
3) Square root is applied to better represent the values. 
Source: Authors’ own calculation. 
Figure 3: Main nanotechnology streams associated to drugs to treat the cancers  
(2000-2012) 
 
Paclitaxel albumin-stabilized nanoparticle 
formulation is also being studied in the 
treatment of other types of cancer. Growing 
trends are also by other chemotherapy agents 
applied by nanotechnology, such as docetaxel, 
gemcitabine and cisplatin. Instead, since 2007 
there is the development of new molecular 
target therapy, a new technological paradigm 
to treat the cancer based on small molecule 
and protein drugs, that has generating a 
revolution in clinical practice (Coccia, 
2012b). Figure 3 shows growing trends of the 
association between target/antiestrogen 
therapy and nanotechnology are by cetuximab 
and tamoxifen. Cetuximab is a monoclonal 
antibody9 that is approved to treat some 
patients with squamous cell carcinoma of the 
head and neck or colorectal cancer. 
Tamoxifen is a type of antiestrogen, a drug 
9   “A type of protein made in the laboratory that can 
bind to substances in the body, including cancer 
cells. There are many kinds of monoclonal 
antibodies. A monoclonal antibody is made so that it 
binds to only one substance. Monoclonal antibodies 
are being used to treat some types of cancer. They 
can be used alone or to carry drugs, toxins, or 
radioactive substances directly to cancer cells” 
(National Cancer Institute, 2013).  
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used to treat certain types of breast cancer and 
to prevent breast cancer.  
It blocks the effects of the hormone estrogen 
in the breast. Tamoxifen is also being studied 
in the treatment of other types of cancer. 
Herceptin (Trastuzumab) is one of the first 
target therapies applied by nanotechnology to 
cancer treatments; in particular, it is approved 
to treat certain types of breast cancer as well 
as some types of gastric or gastroesophageal 
junction adenocarcinoma.  
Herceptin and nanotechnology trend 
achieved a peak in 2009, though now there is 
a declining trend of the technological 
trajectory. The trend of curcumin treatment by 
nanotechnology is growing. This substance 
has a current high interest in 
chemoprevention, in particular for serious 
gastrointestinal diseases such as colonrectum 
cancer (cf. Hull and Logan, 2011 and other 
articles in the issue of Best Practice & 
Research Clinical Gastroenterology, vol. 24 
and 25). In short, Figure 3 shows two main 
technological waves concerning the 
application of anticancer treatments by 
nanotechnology: 
1. The early technological wave is in the 
early 2000s and based on some types of 
chemotherapy agents with a broad 
spectrum of applications to different 
cancers; 
2. The second technological wave appeared 
after 2006, with new nano-technological 
applications in both chemotherapy agents 
and molecular target therapy (e.g. 
lapatinib for breast and other solid 
tumors and cetuximab for head, neck and 
colorectal cancer).  
 
 
Source: Authors’ own calculation. 
Figure 4: Network of main nanotechnology-based chemotherapy agents applied  
in different types of cancer.  
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Figure 4 and 5 show, by a network analysis, 
the field of action of chemotherapy agents or 
molecular target therapy that use 
nanotechnology to treat cancer.  
In particular, Figure 4 shows that there are 
two clusters based on the association of 
chemotherapy agents and nanotechnology: 
general (No. 01 & 06) and specific ones 
(No.02, 03, 04 & 05). 
The first cluster is doxorubicin and 
paclitaxel applied by nanotechnology (see the 
high number and larger thickness of arrows): 
these chemotherapy agents have a broad-
spectrum of action (based on high number of 
citations) on different types of cancers. As a 
matter of fact, doxorubicin has a strong 
connection with brain cancer, whereas 
paclitaxel has a strong association meanly 
with brain, ovarian, breast and lung cancer.  
The second cluster is given by other 
nanotechnology-based chemotherapy agents, 
which have a reduced spectrum of 
applications, more focused on specific 
cancers, such as: gemcitabine for pancreatic 
and brain cancer (the nanotechnology based 
gemcitabine agents also plays a main role to 
treat metastases of brain cancer), cisplatin for 
ovarian cancer, docetaxel for brain and 
ovarian cancer.  
Figure 4 also shows that breast and lung 
cancer have a large volume of research 
records in this field concerning new 
treatments with nanotechnology (larger 
square), whereas nanotechnology associated 
to doxorubicin and paclitaxel is  those more 
frequently cited.   
Figure 5, instead, shows similar results for 
nanotechnology based on molecular target 
therapies and other anticancer substances 
(considering the number and thickness of 
arrows). Similarly to the previous results, 
Figure 5 presents also two groups of 
anticancer treatments based on 
nanotechnology, i.e. widely applied general 
molecular target therapy/substance with 
nanotechnology and specifically applied one. 
The curcumin substance for chemoprevention 
and cancer siRNA therapy applied by 
nanotechnology have a broad spectrum of 
applications on several types of cancer 
(curcumin has a strong connection mainly 
with brain, colon and prostate cancer-based on 
high citations-; siRNA with pancreatic cancer; 
cf. Yang et al., 2012).  
Herceptin via nanotechnology is applied 
mainly on breast cancer, cetuximab on brain 
cancer and lapatinib10 for breast and 
pancreatic cancer. Figure 5 also shows an 
interesting connection between tamoxifen via 
nanotechnology and brain cancer.  
Tamoxifen is most often used to treat or 
prevent breast cancer, however it has also 
been tried for other cancers, including brain 
tumors, however tamoxifen trial to treat brain 
cancer show that the effectiveness of this 
anticancer treatment has high uncertainty. As 
well as,  an interesting connection is between 
lapatinib via nanotechnology and pancreatic 
cancer. In fact, based on in vitro results, 
lapatinib may provide clinical benefit in 
EGFR11 positive pancreatic ductal 
adenocarcinoma (Walsh et al., 2013). 
As far as nanotechnology-based on 
molecular target therapy is concerned, breast, 
brain, lung and colon cancer have a larger 
volume of research records in these fields 
(larger square).  
10 Lapatinib is approved for the treatment of certain 
types of advanced or metastatic breast cancer. 
11 Epidermal growth factor receptor, cf. Coccia 
(2012b). 
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Source: Authors’ own calculation. 
Figure 5: Network of main molecular target therapies applied by nanotechnologies for ground-
breaking treatments in different types of cancers.  
 
To explore the sources of the scientific 
research on ground-breaking applications of 
anticancer drugs via nanotechnology, we spot 
the top 15 performer countries in Figure 6. 
These high performer countries are mainly (in 
decreasing order with standardized value): 
USA, China, Italy, Japan, India, Germany and 
UK. These are also the countries with a high 
intensity of scientific research of anticancer 
drugs by nanotechnology in all specific types 
of cancer. However, Motoyama and Eisler 
(2013) argue that when academic publications 
are divided by number of researcher, the US is 
not the leader but lags behind the Germany 
and the United Kingdom.  
Figure 6 makes a total comparison across 
countries, whereas Figure 7 shows the inner 
specialization of the countries in new 
anticancer drug applications by 
nanotechnology in specific type of cancer.  
Field specialization index γij (Eq. 4) 
indicates the specialization ratio of the 
country i in the specific research field j.  
For instance, Singapore and Italy have a 
higher inner specialization in breast cancer 
(treated by nanotechnology-based anticancer 
drugs) in comparison to other types of cancer, 
Switzerland and Greece in prostate cancer, 
Israel and Taiwan in lung cancer, Japan and 
Israel in colon cancer, China and Switzerland 
in ovarian cancer, Greece and Japan in 
pancreatic cancer and for brain cancer, high 
inner specialization is within Switzerland and 
India. Detailed values for all countries and 
cancer research fields can be found in Table 
1A in the Appendix.   
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Source: Authors’ own calculation. 
Note: Square root is applied to better represent the values.  
Figure 6: Top 15 high performer countries in nanotechnology applied  
for cancer treatments (2000-2012) 
 
 
 
Note: See detailed calculation equations in Section Method of Research.  
Source: Authors’ own calculation. 
Figure 7: Inner specialization of countries (with high value γ) in nanotechnology 
applications to treat specific cancer  
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5. LESSONS LEARNED AND 
CONCLUDING OBSERVATIONS  
Chemotherapy has non-specific effects in 
the body on normal tissues, causes toxicity, 
reduces the quality of life of patients, weakens 
the immune system and can damage in 
irreversible way the recovery power of 
patients. Instead, according to Gao et al. 
(2013): “nanotechnology-based 
chemotherapies seem to have an ability to 
specifically and safely reach tumor foci with 
enhanced efficacy and low toxicity”. In 
particular, nanotechnology tends to support 
the discovery and clinical development of 
novel therapies for oncology focused on 
chemotherapy agents, small molecule and 
protein drugs (target therapy). 
Nanotechnology is contributing to create 
differentiated products and enhance clinical 
practice for new anticancer treatments (cf. 
Bertrand et al., 2013). This groundbreaking 
pattern of nanotechnology in medicine is 
enhanced by mechanism of “ ‘learning via 
diffusion’ …. The increased adoption of a 
technology paves the way for improvement in 
its characteristics” (Sahal as quoted by 
Coccia, 2014). The present paper analyses the 
new trajectories of ground breaking cancer 
treatments based on nanotechnology. Using 
publication and citation data, covering seven 
cancer fields and several types of anticancer 
treatments via nanotechnologies, our study 
shows here that some emerging directions of 
nanoscience and nanotechnology in oncology 
are growing rapidly over time.  
Some main findings of this study are:  
• Technological waves. The first main 
finding, over the studied 13 years, is 
represented by two main technological 
waves concerning the application of 
anticancer treatments by nanotechnology 
(Fig. 3). The early technological wave is in 
the early 2000s and based on some types of 
chemotherapy agents with a broad 
spectrum of applications to different 
cancers (e.g. doxorubicin and paclitaxel), 
while after 2006, the second technological 
wave appeared with narrow applications of 
molecular target therapy by 
nanotechnology (such as cetuximab, 
lapatinib, etc.). These nanotechnology 
waves in medicine are opening new and 
effective treatments for breast, lung, brain 
and colon cancers.  
• High rate of mortality as driver. The 
second main finding is the recognition that, 
since the late 2000s, the sharp increase of 
several technological trajectories of 
nanotechnology-based anticancer drugs 
seems to be driven by high rates of 
mortality of some types of cancers (e.g. 
pancreatic and brain) in order to find more 
effectiveness therapies that increase the 
survival of patients. Hence, most 
importantly, nanotechnology opens a new 
era for anti-cancer treatments where 
mortality of some types of cancer is high 
and traditional drugs /approaches are not 
effective enough. In fact, in brain cancer 
and pancreatic-cancer (where mortality 
rate is high in comparison to the incidence, 
see Tab. 1), although the total research 
output is low, nanotechnology-based 
anticancer treatments seem to play an 
increasingly important role to find ground-
breaking therapies that have high 
effectiveness and low adverse effects.  
• General and specific nanotechnology-
based chemotherapy. The third result is 
given by network analysis, which seems to 
show that there are both general and 
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specific nanotechnology-based 
chemotherapy: the first one is based on 
doxorubicin and paclitaxel applied by 
nanotechnology mainly to treat brain, 
ovarian, breast and lung cancer; the second 
one is based on gemcitabine for pancreatic 
and brain cancer, cisplatin for ovarian 
cancer, docetaxel for brain and ovarian 
cancer.  
• Likely new directions of path-breaking 
nanotechnology-based molecular cancer 
therapy. These new directions, detected by 
network analysis, seem to be tamoxifen via 
nanotechnology to treat brain cancer and 
lapatinib via nanotechnology to treat 
pancreatic cancer. 
• Specialization of countries. Another result 
is that some countries show an inner 
specialization in nanotechnology-based 
treatments for specific type of cancer, such 
as Singapore and Italy for breast cancer, 
Switzerland and Greece for prostate 
cancer, Israel and Taiwan for lung cancer, 
Japan and Israel for colon cancer, China12 
and Switzerland for ovarian cancer, Greece 
and Japan for pancreatic cancer and 
Switzerland and India for brain cancer. 
12 cf. Motoyama et al. (2014).  
These results show vital patterns of 
nanoscience and nanotechnology in oncology. 
The technological trajectories detected  may 
be the foundation for a continuous progress of 
nanotechnology in biomedicine, supported by 
a high intensity of scientific and technological 
production growth that accumulates technical 
knowledge and spurs ground-breaking and 
efficient anticancer treatments.  
Hence, new nano-technological avenues are 
paving a pervasive diffusion in biomedical 
sciences and generating a revolution in 
clinical practice to treat (and we hope to cure) 
cancers in order to lead to longer, better and 
healthier living of societies in a not-too-
distant future (Mangematin and Walsh, 2012). 
However, emerging trajectories of 
nanoscience and nanotechnology are also 
problematic in medicine because have several 
and unpredictable directions, in particular 
when we know that in the life science systems 
other things are often not equal and can 
change in the presence of turbulent and fast-
running technological change. 
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APPENDIX 
 
 
 
 
Note: The logarithm of publications is taken to better present the values.  
Source: Authors’ own calculation. 
 
Figure 1A: Citations of nanotechnology in cancer treatments per different typology 
of cancer (2000-2012)  
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Table 1A: Specialization of countries in specific cancer based on new applications of anticancer 
drugs via ground-breaking nanotechnology (2000-2012) 
 
COUNTRY 
breast-
cancer 
prostate-
cancer 
lung-
cancer 
colon-
cancer 
ovarian-
cancer 
pancreatic-
cancer 
brain-
cancer 
Australia -0.174 -0.050 -0.057 0.046 -0.022 -0.035 -0.026 
Canada -0.021 0.024 -0.016 -0.030 0.040 -0.010 -0.001 
China -0.003 -0.041 0.038 0.011 0.065 0.014 -0.023 
France 0.045 -0.005 -0.028 -0.006 -0.060 0.012 -0.014 
Germany 0.028 0.019 -0.018 -0.019 -0.023 -0.012 0.023 
Greece -0.113 0.070 -0.055 -0.011 -0.022 0.164 -0.042 
India -0.028 -0.053 0.025 -0.029 -0.058 0.027 0.044 
Iran -0.064 -0.017 0.072 0.042 0.012 0.016 -0.031 
Israel -0.069 0.035 0.148 0.125 -0.060 -0.002 -0.042 
Italy 0.093 0.003 0.000 -0.006 -0.030 0.009 0.015 
Japan -0.004 -0.028 0.025 0.145 -0.002 0.069 0.016 
Netherlands 0.070 -0.029 -0.091 -0.025 -0.062 0.030 -0.028 
Singapore 0.134 -0.110 0.028 0.122 0.027 0.035 0.027 
South Korea 0.050 0.065 0.079 0.048 0.006 -0.017 0.006 
Spain -0.002 -0.065 -0.104 0.017 -0.064 0.006 0.003 
Sweden -0.073 0.060 -0.042 0.035 0.043 -0.033 -0.042 
Switzerland -0.027 0.112 0.042 0.112 0.048 -0.033 0.073 
Taiwan -0.072 -0.065 0.108 0.106 -0.021 -0.036 -0.035 
United Kingdom -0.008 -0.040 -0.025 0.024 -0.029 -0.015 -0.007 
United States -0.012 0.032 0.007 -0.009 0.020 0.013 0.004 
 
Note:  if i is the country and j is the research field (e.g. Breast cancer), the location of the countries in the 
map is given by the index γ that indicates the high specialization of the country i in the specific research 
field j 
𝐶𝑖𝑗 = 𝑃𝑢𝑏𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑗𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑖 ;  𝑊𝑗 = 𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑏𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑗𝑃𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑊𝑜𝑟𝑙𝑑𝑤𝑖𝑑𝑒 ;  𝛾𝑖𝑗 = 𝐶𝑖𝑗 − 𝑊𝑗;                          𝑗 = 1, … ,𝑛. 
In Bold the countries with the highest value γ; moreover, if the index γ>0 means high specialization in the 
scientific research in this type of cancer, whereas if γ < 0 means that there is lower specialization. High 
values γ means a higher intensive research activity in the specific cancer area. 
Source: Authors’ own calculation. 
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